摘要：

This article presents the results of a meta-analysis of all published randomised controlled trials done on the anti-obesity drug rimonabant. Weight loss of 5-10 percent of bodyweight is linked with improvements in cardiovascular health and lowers the incidence of type 2 diabetes. Rimonabant is available in Europe but has not yet been approved by the U.S. Food and Drug Administration due to concerns over its side effects of increasing depression and suicidal thoughts. The study found that 20 milligrams per day of rimonabant increases the risk of psychiatric adverse events and this should cause increased caution by physicians.

展开